Aducanumab in Alzheimer's Disease: A Comparative Study of Its Effects on Dementia and Mild Cognitive Impairment

Alzheimer's disease (AD) is the leading cause of dementia, characterized by progressive cognitive decline. Cholinesterase inhibitors are commonly used to manage symptoms but have limited efficacy as the disease progresses. Aducanumab, a monoclonal antibody targeting amyloid-β (Aβ) plaques, has...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Curēus (Palo Alto, CA) CA), 2024-12, Vol.16 (12), p.e75907
Hauptverfasser:	Medel Sánchez, Andrea, Ortiz Hernández, Arturo, Moreno Moreno, Ramiro A, Salas López, Diana, Madrigal Gómez, Luz E, Dominguez Ibarra, Anna K, Gutiérrez Rojas, Beatriz A, Garcia Navarro, Cesar O, Moreno Becerril, Gerardo T, Montelongo Quevedo, Mauricio, Flores Valdés, Jose R
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!